Search
XEN-2174
go.drugbank.com/drugs/DB05012ExperimentalIn episodes of pain, inhibition of NET by XEN-2174 elevates the levels of NE leading to the activation of inhibitory pathways preventing pain signals from reaching the brain.
Zolazepam
go.drugbank.com/drugs/DB11555ExperimentalVet approvedIt is around four times the potency of diazepam but it is both water-soluble and un-ionized at physiological pH meaning that its onset is very fast. … Zolazepam is typically used in combination with the NMDA antagonist tiletamine or the α2 adrenoceptor agonist xylazine.
Pentosan polysulfate
go.drugbank.com/drugs/DB00686ApprovedInvestigationalPentosan polysulfate is a sulfated pentosyl polysaccharide with heparin-like properties.
Synonyms: 4-O-METHYL-.ALPHA.-D-GLUCURONO-.BETA.-D-XYLAN, HYDROGEN SULFATE, 4-O-METHYL-.ALPHA.-D-GLUCURONO-.BETA.-D-XYLAN, HYDROGEN SULPHATETovecimig
go.drugbank.com/drugs/DB30220InvestigationalNOV1501 is under investigation in clinical trial NCT03292783 (This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended
Azelnidipine
go.drugbank.com/drugs/DB09230InvestigationalIt is currently being studied for post-ischemic stroke management [L1380]. … It is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan.
WP-1301
go.drugbank.com/drugs/DB17702ExperimentalIt binds to an MHC class II molecule and is recognized by a Factor VIII-specific T cell.[L46138]
Ultevursen
go.drugbank.com/drugs/DB17835InvestigationalIt was developed by ProQR Therapeutics and is being investigated for the treatment of retinitis pigmentosa.
Talaporfin
go.drugbank.com/drugs/DB11812InvestigationalTalaporfin has been investigated for the treatment of Port-Wine Stain and Benign Prostatic Hyperplasia.
Categories: Heterocyclic Compounds with 4 or More RingsFoscenvivint
go.drugbank.com/drugs/DB15034InvestigationalPRI-724 is under investigation in clinical trial NCT03620474 (Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis).
AVI-4065
go.drugbank.com/drugs/DB05620InvestigationalIt was developed by Sarepta Therapeutics, Inc. After phase II trials it was cancelled due to lack of potency. [L2917]